|

Osimertinib mesylate Clinical Trials

2 actively recruiting trials

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • Shanghai JMT-Bio Inc.1
  • Shanghai Hengrui Pharmaceutical Co., Ltd.1

Indications

  • Lung Cancer2
  • Non Small Cell Lung Cancer2
  • Cancer2

Other2 trials

A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
Phase 2
A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.